“My team and I have been collaborating with Oxeltis since 2014, successfully delivering a number of key medicinal chemistry projects supporting Atea’s discovery and pharmaceutical development efforts. Throughout this collaboration, the Oxeltis team has consistently demonstrated strong expertise in the synthesis of complex organic molecules, alongside valuable contributions to compound design and SAR studies, supported by both medicinal chemistry insight and computational analysis. Their chemists have worked across a broad range of chemical modalities, including nucleosides, carbohydrates, macrocyclic and heterocyclic compounds, as well as other small molecules. The team’s motivation, dedication, and scientific rigor have been exemplary. Communication has always been efficient and collaborative, supported by high-quality reports and presentations, ultimately leading to meaningful project outcomes. Importantly, Oxeltis’ medicinal and synthetic chemistry work has contributed to the selection of high-value clinical candidates.”
Adel Moussa, Executive Vice President, Chemistry, Atea Pharmaceuticals, Boston, MA, USA
“The modified phosphoramidites synthesized by Oxeltis for our oligonucleotide program showed excellent purity and enhanced activity when tested in our systems. Timely synthesis and clear communication by Oxeltis greatly facilitated our project’s progress.”
Joel Kaye, PhD, Chief Development Officer, 1E Therapeutics Ltd.
“Over the years, I have collaborated several times with Oxeltis, and I was very pleased with the timely delivery and the quality of the compounds they made”
Prof. Em. Dr. Piet HERDEWYN, KUL, Catholic University of Leuven, Belgium
« We contracted Oxeltis to synthesize a lead compound which proved problematic for others. In meeting with the Oxeltis team we walked away very confident that they could handle the synthesis and deliver based on our timeline needs. The Oxeltis team exceeded our expectations. We are extremely satisfied and highly recommend them for your synthesis and medicinal chemistry needs. »
Dr. Olumide Kayode, CEO, Geminus Therapeutics an Early Charm Ventures company. Baltimore – MD, USA
“What we really appreciated with Oxeltis is the follow-up that the company provides all along the synthesis process and even after. They really care about the quality of the service: they contact you to keep you updated about the production, and want to make sure you are satisfied once the product has been delivered. We have been extremely satisfied with this company and strongly recommend it.”
Dr Olivier Chassande, CNRS, Laboratoire de Bioingénierie Tissulaire (BioTis), Université Bordeaux Ségalen, France »
« We contracted Oxeltis services in order to enhance/modify emissive and absorption spectrum properties of a reagent in our innovative diagnostic kit.Oxeltis team understood immediately our needs and proposed us an innovative optimization approach that paid off quickly. After 3 months we had reached our goals for this new reagent. Therefore, we strongly recommend OXELTIS for their professionalism and their ability to solve complex optimization of physico-chemical properties of small molecules. »
Henri Champseix, Co-founder and CTO, BIT-C2 Diagnostics.
Other clients and programs in Europe and North America are currently confidential.